


wherein R₁ are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl; R₃ groups are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl

R_4 groups are each independently selected from NR_2 , O and S; and R_2 groups are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy and substituted or unsubstituted acyl, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

2. (Original) The compound according to claim 1, having the following formula II:



wherein R_1 , R_2 , R_3 and R_4 are as defined in claim 1.


3. (Currently Amended) The compound according to ~~[[claims]]~~ claim 1 ~~[[or 2]]~~, wherein R_1 are each independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted alkylidene.

4. (Currently Amended) The compound according to ~~any of claims~~ claim 1 ~~[[to 3]]~~, wherein R_2 are each independently selected from H and substituted or unsubstituted alkyl.

5. (Currently Amended) The compound according to ~~any of the preceding claims~~ claim 1, wherein R₃ are each independently selected from H and substituted or unsubstituted aryl.

6. (Currently Amended) The compound according to ~~any of the preceding claims~~ claim 1, wherein R₄ are each O.

7. (Currently Amended) The compound according to ~~any of the preceding claims~~ claim 1 having the following formula



or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.


Attorney's Docket No.: 14700-008US1 / F/USP288234

Attorney's Docket No.: 14700-008US1 / F/USP288234

Attorney's Docket No.: 14700-008US1 / F/USP288234

Attorney's Docket No.: 14700-008US1 / F/USP288234

Attorney's Docket No.: 14700-008US1 / F/USP288234



Attorney's Docket No.: 14700-008US1 / F/USP288234

Attorney's Docket No.: 14700-008US1 / F/USP288234

C=Cc1cc(O)c2nc(Cc3oc(C)cn3C4=CC=CC=C4)c(Cn5cnc6c(C(=O)N[C@@H](C)C(C)C)C(=O)N[C@@H](C)C(C)C)c6o5)c1

13. (Original) A process according to claim 12, wherein the microorganism is the substantially pure culture strain ES7-008, available under accession number CECT 3358, from the Colección Espanola de Cultivos Tipo at the University of Valencia, Spain.

15. (Cancelled)

16. (Cancelled)

17. (Currently Amended) A method of treatment of cancer which comprises administering an effective amount of a compound as defined in ~~any of claims~~ claim 1 ~~[[to 8]]~~, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.